MARKET

BIOA

BIOA

BioAge Labs Inc.
NASDAQ
17.66
-1.06
-5.64%
After Hours: 17.66 0 0.00% 19:54 05/15 EDT
OPEN
18.17
PREV CLOSE
18.72
HIGH
18.28
LOW
17.37
VOLUME
481.58K
TURNOVER
--
52 WEEK HIGH
24.00
52 WEEK LOW
3.670
MARKET CAP
785.04M
P/E (TTM)
-7.3433
1D
5D
1M
3M
1Y
5Y
1D
AMD, Under Armour downgraded: Wall Street’s top analyst calls
TipRanks · 3d ago
BioAge Labs initiated with a Buy at BTIG
TipRanks · 3d ago
Earnings Beat: BioAge Labs, Inc. (NASDAQ:BIOA) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Simply Wall St · 4d ago
Analysts Offer Insights on Healthcare Companies: BioAge Labs, Inc. (BIOA) and Lexeo Therapeutics, Inc. (LXEO)
TipRanks · 4d ago
BioAge Labs posts R&D Day presentation on BGE-102 program
PUBT · 4d ago
BioAge Labs: Analyst Reiterates Buy on Best-in-Class Potential of Lead NLRP3 Inhibitor BGE-102 After Encouraging Phase 1/2 Data
TipRanks · 5d ago
Weekly Report: what happened at BIOA last week (0504-0508)?
Weekly Report · 5d ago
Analysts Offer Insights on Healthcare Companies: Amylyx Pharmaceuticals Inc (AMLX), BioAge Labs, Inc. (BIOA) and Pharvaris (PHVS)
TipRanks · 6d ago
More
About BIOA
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its lead product is BGE-102, a structurally novel, orally available small molecule NLRP3 inhibitor with high potency and brain penetration. In preclinical obesity models, BGE-102 resulted in weight loss as both a monotherapy and in combination with a GLP-1R agonist. Its pipeline includes novel, orally available, brain-penetrant small-molecule NLRP3 inhibitors to treat metabolic diseases and conditions driven by neuroinflammation, as well as novel APJ agonists for metabolic disorders. In preclinical obesity models, APJ agonism has demonstrated the ability to more than double the weight loss induced by a GLP-1R agonist while also restoring healthy body composition and improving muscle function.

Webull offers BioAge Labs, Inc. stock information, including NASDAQ: BIOA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BIOA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BIOA stock methods without spending real money on the virtual paper trading platform.